Univariate and multivariate analysis of clinical characteristics affecting EFS and OS by RARα 2 expression in TT2 and TT3
| Variable . | n/N (%) . | EFS . | OS . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| Univariate | |||||
| Age ≥ 65 y | 0.75 (0.29, 1.97) | .562 | 0.93 (0.31, 2.76) | .889 | |
| LDH ≥ 190 U/L | 22/80 (28) | 2.27 (1.11, 4.64) | .024 | 2.38 (1.03, 5.52) | .043 |
| B2M ≥ 0.3 μM | 1.32 (0.66, 2.65) | .433 | 1.48 (0.64, 3.41) | .362 | |
| B2M > 0.47 μM | 1.21 (0.50, 2.94) | .678 | 1.26 (0.43, 3.73) | .674 | |
| Albumin < 35 g/dL | 0.70 (0.25, 2.01) | .512 | 0.85 (0.25, 2.87) | .793 | |
| Creatinine ≥ 176.8 μM | 1.53 (0.53, 4.40) | .427 | 1.14 (0.27, 4.91) | .859 | |
| CRP ≥ 8.0 mg/L | 1.32 (0.62, 2.83) | .473 | 1.29 (0.52, 3.19) | .588 | |
| Hb < 100 g/L | 1.60 (0.76, 3.37) | .213 | 1.31 (0.52, 3.28) | .561 | |
| Cytogenetic abnormalities | 29/79 (37) | 2.25 (1.09, 4.65) | .028 | 3.62 (1.51, 8.68) | .004 |
| RARα2+ | 26/80 (33) | 2.13 (1.06, 4.27) | .034 | 3.33 (1.42, 7.81) | .006 |
| 210764_at < 738 | 10/80 (13) | 3.80 (1.61, 8.94) | .002 | 4.74 (1.79, 12.52) | .002 |
| 70-gene–defined GEP high risk | 5/80 (6) | 5.26 (1.73, 15.97) | .003 | 7.59 (2.36, 24.43) | < .001 |
| Multivariate | |||||
| Cytogenetic abnormalities | 29/79 (37) | 2.67 (1.26, 5.64) | .01 | 4.41 (1.75,11.10) | .002 |
| RARα2+ | 26/79 (33) | 2.22 (1.07, 4.58) | .032 | 3.19 (1.32, 7.68) | .01 |
| 210764_at < 738 | 10/79 (13) | 3.66 (1.50, 8.91) | .004 | 3.93 (1.43, 10.84) | .008 |
| Variable . | n/N (%) . | EFS . | OS . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| Univariate | |||||
| Age ≥ 65 y | 0.75 (0.29, 1.97) | .562 | 0.93 (0.31, 2.76) | .889 | |
| LDH ≥ 190 U/L | 22/80 (28) | 2.27 (1.11, 4.64) | .024 | 2.38 (1.03, 5.52) | .043 |
| B2M ≥ 0.3 μM | 1.32 (0.66, 2.65) | .433 | 1.48 (0.64, 3.41) | .362 | |
| B2M > 0.47 μM | 1.21 (0.50, 2.94) | .678 | 1.26 (0.43, 3.73) | .674 | |
| Albumin < 35 g/dL | 0.70 (0.25, 2.01) | .512 | 0.85 (0.25, 2.87) | .793 | |
| Creatinine ≥ 176.8 μM | 1.53 (0.53, 4.40) | .427 | 1.14 (0.27, 4.91) | .859 | |
| CRP ≥ 8.0 mg/L | 1.32 (0.62, 2.83) | .473 | 1.29 (0.52, 3.19) | .588 | |
| Hb < 100 g/L | 1.60 (0.76, 3.37) | .213 | 1.31 (0.52, 3.28) | .561 | |
| Cytogenetic abnormalities | 29/79 (37) | 2.25 (1.09, 4.65) | .028 | 3.62 (1.51, 8.68) | .004 |
| RARα2+ | 26/80 (33) | 2.13 (1.06, 4.27) | .034 | 3.33 (1.42, 7.81) | .006 |
| 210764_at < 738 | 10/80 (13) | 3.80 (1.61, 8.94) | .002 | 4.74 (1.79, 12.52) | .002 |
| 70-gene–defined GEP high risk | 5/80 (6) | 5.26 (1.73, 15.97) | .003 | 7.59 (2.36, 24.43) | < .001 |
| Multivariate | |||||
| Cytogenetic abnormalities | 29/79 (37) | 2.67 (1.26, 5.64) | .01 | 4.41 (1.75,11.10) | .002 |
| RARα2+ | 26/79 (33) | 2.22 (1.07, 4.58) | .032 | 3.19 (1.32, 7.68) | .01 |
| 210764_at < 738 | 10/79 (13) | 3.66 (1.50, 8.91) | .004 | 3.93 (1.43, 10.84) | .008 |
P values are from the Wald χ2 test in Cox regression. All univariate P values are reported regardless of significance. Multivariate model uses stepwise selection with entry level .1, and variable remains if it meets the .05 level. A multivariate P value greater than .05 indicates variable forced into model with significant variables chosen using stepwise selection.
HR indicates hazard ratio; 95% CI, 95% confidence interval; LDH, lactate dehydrogenase; B2M, β2-microglobulin; CRP, C-reactive protein; Hb, hemoglobin; and GEP, gene expression profiling.